Thyrocare Technologies Ltd
Mon 2/02/2026,15:59:55 | NSE : THYROCARE
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 404.95
Previous Close
₹ 400.05
Volume
452441
Mkt Cap ( Rs. Cr)
₹6302.01
High
₹ 405.10
Low
₹ 381.05
52 Week High
₹ 536.13
52 Week Low
₹ 219.11
Book Value Per Share
₹ 33.57
Dividend Yield
5.24
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Thyrocare Technologies Ltd
Your Vote -
Buy
78.43%
Hold
7.84%
Sell
13.73%
78.43%
51 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
395.95
1890
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
1890
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Thyrocare Technologies Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Thyrocare Tech. - Copy of Newspaper Publication
-
Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Thyrocare Tech. Q3 net profit up 36.91% at Rs 26.15 cr
-
Thyrocare Tech. - General Updates
-
Thyrocare Tech. - Investor Presentation
-
Thyrocare Tech. - Press Release
-
Thyrocare Tech. - Outcome of Board Meeting
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Thyrocare Tech. - Financial Results For The Quarter And Nine Months Ended December 31, 2025.
-
Thyrocare Tech. - Board Meeting Outcome for Outcome Of The Board Meeting Held On January 28, 2026\r\n
-
Thyrocare Tech. - Updates
-
Thyrocare Tech. - Press Release - Thyrocare Onboards Madhuri Dixit As The Brand\r\nAmbassador To Inspire Health And Well-Bein
-
Thyrocare Tech. - Updates
-
Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Thyrocare Tech. - Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial
-
Thyrocare Tech. has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025
-
Thyrocare Tech. - Updates
-
Thyrocare Tech. - Change Of Name Of M S K A & Associates Upon Conversion Of Firm Into LLP
-
Thyrocare Tech. - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Thyrocare Tech. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Thyrocare Tech. - Change in Management
-
Thyrocare Tech. - Appointment
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Change in Management
-
Thyrocare Tech. - Trading Window
-
Thyrocare Tech. - Appointment
-
Thyrocare Tech. - Change in Management
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Change in Management
-
Thyrocare Tech. has submitted to BSE the Shareholding Pattern for the Period Ended December 01, 2025
-
Thyrocare Tech. has submitted to BSE the Shareholding Pattern for the Period Ended December 01, 2025
-
Thyrocare Tech. - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulatio
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Allotment
-
Thyrocare Tech. - Allotment of Securities
-
Thyrocare Tech. - Allotment of Securities
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Allotment
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Change in Management
-
Thyrocare Tech. - Change in Management
-
Thyrocare Tech. - Copy of Newspaper Publication
-
Thyrocare Tech. - Amendment to AOA/MOA
-
Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
-
Thyrocare Tech. - Corporate Action - Fixes Record Date For Bonus Issue
-
Thyrocare Tech. - Record Date
-
Thyrocare Tech. - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Thyrocare Tech. - Shareholders meeting
-
Thyrocare Tech. - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
-
Thyrocare Tech. - Clarification On Significant Movement In Volume Of Shares Of The Company
-
Thyrocare Tech. - Clarification sought from Thyrocare Technologies Ltd
-
Thyrocare Tech. - Spurt in Volume
-
Thyrocare Tech. - Spurt in Volume
-
Thyrocare Tech. - Disclosure under SEBI Takeover Regulations
-
Thyrocare Tech. - Disclosure under SEBI Takeover Regulations
-
Thyrocare Technologies Ltd
-
Thyrocare Technologies
-
Thyrocare to acquire Vimta's Diagnostic & Pathological svcs business on a slump sale basis
-
Thyrocare Technologies
-
Thyrocare board approves share buyback
Key fundamentals
Evaluate the intrinsic value of Thyrocare Technologies Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 537.1 | 533.58 | 521.04 | 520.7 | 445.46 |
| Liabilities | 537.1 | 533.58 | 521.04 | 520.7 | 445.46 |
| Equity | 52.99 | 52.95 | 52.93 | 52.9 | 52.87 |
| Gross Profit | 187.02 | 133.88 | 112.01 | 230.83 | 170.74 |
| Net Profit | 95.78 | 71.14 | 56.97 | 152.05 | 119.77 |
| Cash From Operating Activities | 190.76 | 155.19 | 120.02 | 105.68 | 110.41 |
| NPM(%) | 15.12 | 13.57 | 11.71 | 27.07 | 25.25 |
| Revenue | 633.1 | 524.02 | 486.46 | 561.53 | 474.27 |
| Expenses | 446.08 | 390.14 | 374.45 | 330.7 | 303.53 |
| ROE(%) | 17.92 | 13.31 | 10.66 | 28.45 | 22.41 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 24 Oct 2025 | 7 | 70 | 5.3 | 1264.6 |
| 25 Jul 2025 | 21 | 210 | 5.3 | 769.2 |
| 16 Aug 2024 | 18 | 180 | 5.3 | 647.25 |
| 20 Apr 2023 | 18 | 180 | 5.3 | 475.9 |
| 11 May 2022 | 15 | 150 | 5.3 | 770.95 |
| 17 Jun 2021 | 15 | 150 | 5.3 | 1063.6 |
| 12 Nov 2020 | 10 | 100 | 5.3 | 1137.65 |
| 21 Nov 2019 | 5 | 50 | 5.3 | 558.55 |
| 14 Aug 2019 | 20 | 200 | 5.3 | 434.7 |
| 02 Aug 2018 | 5 | 50 | 5.3 | 668.95 |
| 15 Feb 2018 | 5 | 50 | 5.3 | 676.2 |
| 03 Aug 2017 | 5 | 50 | 5.3 | 735.45 |
| 08 Feb 2017 | 5 | 50 | 5.3 | 709 |
| 01 Sep 2016 | 2.5 | 25 | 5.3 | 602 |
Peers
Other companies within the same industry or sector that are comparable to Thyrocare Technologies Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 683.60 | -1.06 | 0.00 | 228.40 | 301.39 | 0.73 |
| Lotus Eye Hospital and Institute Ltd | 122.09 | -5.00 | 381.53 | 832.27 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.95 | -1.00 | 0.00 | 5221.09 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 585.80 | 2.86 | 0.00 | 784.85 | -604.77 | 0.00 |
Company Info
The Company was incorporated as Thyrocare Technologies Limited on January 28, 2000 at Mumbai as a public limited company under the Companies Act, 1956. the Company was issued a certificate of commencement of business from the RoC on March 7, 2000. Major events and milestones of the Company : 2000 -The Company was incorporated in the name and style of "Thyrocare Technologies Limited' and received a certificate for commencement of operations. 2001 -The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005 -The Company received NABL accreditation. 2006 -The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007 -The Company receives accreditation from the College of American Pathologists (CAP). 2010 -The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1,250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011 -The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012 -NVP acquired certain Equity Shares aggregating to 1,200 million from certain entities. 2013 -EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation. 2014 -The Company had installed, India's first and the world's longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations. 2015 -The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception. 2016 -Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities. 2024 -Thyrocare Technologies Completed acquisition of Think Health Diagnostic Private Limited. 2025-The Company has issued Bonus Shares in the Ratio of 2:1.
The Company was incorporated as Thyrocare Technologies Limited on January 28, 2000 at Mumbai as a public limited company under the Companies Act, 1956. the Company was issued a certificate of commencement of business from the RoC on March 7, 2000. Major events and milestones of the Company : 2000 -The Company was incorporated in the name and style of "Thyrocare Technologies Limited' and received a certificate for commencement of operations. 2001 -The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005 -The Company received NABL accreditation. 2006 -The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007 -The Company receives accreditation from the College of American Pathologists (CAP). 2010 -The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1,250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011 -The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012 -NVP acquired certain Equity Shares aggregating to 1,200 million from certain entities. 2013 -EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation. 2014 -The Company had installed, India's first and the world's longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations. 2015 -The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception. 2016 -Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities. 2024 -Thyrocare Technologies Completed acquisition of Think Health Diagnostic Private Limited. 2025-The Company has issued Bonus Shares in the Ratio of 2:1.
Read More
Parent Organisation
Thyrocare Technologies Ltd.
Founded
28/01/2000
Managing Director
Mr.Rahul Guha
NSE Symbol
THYROCAREEQ
FAQ
The current price of Thyrocare Technologies Ltd is ₹ 395.95.
The 52-week high for Thyrocare Technologies Ltd is ₹ 405.10 and the 52-week low is ₹ 381.05.
The market capitalization of Thyrocare Technologies Ltd is currently ₹ 6302.01. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Thyrocare Technologies Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Thyrocare Technologies Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Thyrocare Technologies Ltd shares.
The CEO of Thyrocare Technologies Ltd is Mr.Rahul Guha, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
